InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (19 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
19
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Albers Jeffrey W., Chairman & CEO. Director active across 3 companies, notably Blueprint Medicines Corp. In total, 59 filings have been published. Split: 0 buy · 19 sells. Total volume traded: €7.6m. Activity tracked since 12 May 2021. The latest transaction was filed on 7 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Albers Jeffrey W.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations59 total
5,000 shares@ US$10.39Common StockSEC:0001636282-26-000102:0
5,000 shares@ US$104.47Common StockSEC:0001636282-26-000102:1
8,000 shares@ US$104.38Common StockSEC:0001636282-26-000102:2
10,000 shares@ US$104.68Common StockSEC:0001636282-26-000102:3
5,000 shares@ US$14.187.2% of flowCommon StockSEC:0001193125-25-311505:0
5,000 shares@ US$10.346.2% of flowCommon StockSEC:0001193125-25-238130:0
5,000 shares@ US$59.189835.3% of flowCommon StockSEC:0001193125-25-238130:1
5,777 sharesCommon StockSEC:0001104659-25-069377:0
3,902 shares@ US$128.125.6% of flowCommon StockSEC:0001415889-25-018086:0
6,349 shares@ US$10.347.4% of flowCommon StockSEC:0000950170-25-081198:0
5,000 shares@ US$36.051.9% of flowCommon StockSEC:0001415889-25-014862:0
4,350 shares@ US$101.024.7% of flowCommon StockSEC:0001415889-25-014862:1
650 shares@ US$101.930.7% of flowCommon StockSEC:0001415889-25-014862:2
5,766 shares@ US$88.806.2% of flowCommon StockSEC:0001415889-25-008211:0
7,500 shares@ US$36.053.2% of flowCommon StockSEC:0001415889-25-008112:0
10,000 shares@ US$36.054.5% of flowCommon StockSEC:0001415889-25-001989:0
5,000 shares@ US$36.052.3% of flowCommon StockSEC:0001415889-25-001507:0
15,000 shares@ US$36.056.7% of flowCommon StockSEC:0001415889-24-029971:0
5,000 shares@ US$36.052.2% of flowCommon StockSEC:0001415889-24-026594:0
5,000 shares@ US$102.006.1% of flowCommon StockSEC:0001415889-24-026594:1
6,700 shares@ US$36.763195.7% of flowCommon StockSEC:0001636282-24-000089:0
300 shares@ US$36.434.3% of flowCommon StockSEC:0001636282-24-000070:0
10,000 shares@ US$36.054.2% of flowCommon StockSEC:0001415889-24-023204:0
5,000 shares@ US$10.346.4% of flowCommon StockSEC:0000950170-24-100660:0
2,242 shares0Common StockSEC:0001415889-24-016987:0
25 of 59 declarations
About Albers Jeffrey W.
Jeffrey W. Albers is Chief Executive Officer. He has filed 55 filings in total, and across the recent sample of 55 filings between 2021-05-14 and 2025-12-08, sales total 5558213 EUR and the most common transaction type is option exercise. His filings concern Blueprint Medicines Corp, Kymera Therapeutics, Inc. and Spyre Therapeutics, Inc., and his largest recent filings are with Blueprint Medicines Corp.
